Reverse engineering of the low temperature-sensitive liposome (LTSL) for treating cancer

Biomaterials for Cancer Therapeutics: Diagnosis, Prevention and Therapy

Volumn , Issue , 2013, Pages 270-348

  Needham, D ^a,b  

^a Duke University   (United States)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Low temperature sensitive liposome; Reverse engineering

Indexed keywords

EID: 84902388797     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1533/9780857096760.3.270     Document Type: Chapter

References (160)

1. Kong G., Anyarambhatla G., Petros W.P., Braun R.D., Colvin O.M., Needham D., Dewhirst M.W. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: Importance of triggered drug release. Cancer Research 2000, 60(24):6950-6957.
2. Needham D., Anyarambhatla G., Kong G., Dewhirst M.W. A new temperature-sensitive liposome for use with mild hyperthermia:Characterization and testing in a human tumor xenograft model. Cancer Research 2000, 60(5):1197-1201.
3. Lasic D.D., Needham D. The "Stealth" liposome: A prototypical biomaterial. Chemical Reviews 1995, 95(8):2601-2628.
4. Chen Q., Tong S., Dewhirst M.W., Yuan F. Targeting tumor microvessels using doxorubicin encapsulated in a novel thermosensitive liposome. Molecular Cancer Therapeutics 2004, 3(10):1311-1317.
5. Corporation Celsion Available from:. http://www.celsion.com.
6. Ashby M.F., Jones D.R.H. Design with Materials,in Engineering Materials 2: An Introduction to Microstructures, Processing and Design 2006, Chapter 27, Elsevier, Oxford, UK.
7. Sandham T. MK1 Cortina Gearbox Rebuild http://freespace.virgin.net/tommy.sandham/gearbox.jpg.
8. Landon C., Park J.Y., Needham D., Dewhirst M.W. Nanoscale drug delivery and hyperthermia: The materials design and preclinical and clinical testing of low temperature-sensitive liposomes used in combination with mild hyperthermia in the treatment of local cancer. The Open Nanomedicine Journal 'Therapeutic Approaches and Drug Delivery 2011, 3:38-64.
9. Manzoor A.A., Lindner L.H., Landon C.D., Park J.Y., Simnick A.J., Dreher M.R., Das S., Hanna G., Park W., Chilkoti A., Koning G.A., ten Hagen T.L.M., Needham D., Dewhirst M.W. Overcoming limitations in nanoparticle drug delivery: Triggered, intravascular release to improve drug penetration into tumors. Cancer Research 2012, doi:10.1158/0008-5472.CAN-12-1683.
10. Mills J.K., Needham D. The materials engineering of temperature-sensitive liposomes. Methods Enzymol 2004, 387:82-113.
11. Needham D., Dewhirst M.W. The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. Advanced Drug Delivery Reviews 2001, 53(3):285-305.
12. Ponce A., Needham D. Nanoscale drug delivery vehicles for solid tumors: A new paradigm for localized drug delivery. Nanotechnology for Cancer Therapeutics 2006, CRC Press. M.M. Amji (Ed.).
13. Needham D., Park J.Y., Wright A.M., Tong J. Materials characterization of the low temperature sensitive liposome (LTSL): Effects of lipid composition (lysolipid and DSPE-PEG2000) on the thermal transition and release of doxorubicin. Faraday Discuss. 2013, 161:515-534.
14. Needham D., Dewhirst M.W. Materials science and engineering of the low temperature sensitive liposome (LTSL): Composition-structure-property relationships that underlie its design and performance. Smart Materials for Drug Delivery 2013, Royal Society of Chemistry. p. 33. C. Alvarez-Lorenzo, A. Concheiro (Eds.).
15. Anyarambhatla G.R., Needham D. Enhancement of the phase transition permeability of DPPC liposomes by incorporation of MPPC: A new temperature-sensitive liposome for use with mild hyperthermia. Journal of Liposome Research 1999, 9(4):491-506.
16. Haest C.W., de Gier J., van Es G.A., Verkleij A.J., van Deenen L.L. Fragility of the permeability barrier of Escherichia coli. Biochimica et Biophysica Acta 1972, 288(1):43-53.
17. Papahadjopoulos D., Jacobson K., Nir S., Isac T. Phase transitions in phospholipid vesicles. Fluorescence polarization and permeability measurements concerning the effect of temperature and cholesterol. Biochimica et Biophysica Acta 1973, 311(3):330-348.
18. Mouritsen O.G., Zuckermann M.J. Model of interfacial melting. Physical Review Letters 1987, 58(4):389-392.
19. Needham D., Stoicheva N., Zhelev D.V. Exchange of monooleoylphosphatidylcholine as monomer and micelle with membranes containing poly(ethylene glycol)-lipid. Biophysical Journal 1997, 73(5):2615-2629.
20. Mills J.K. Triggered release of liposome contents: Mechanisms involved in membrane permeability and compromise. Department of Mechanical Engineering and Materials Science 2002, Duke University.
21. Mills J.K., Needham D. Lysolipid incorporation in dipalmitoylphosphatidylcholine bilayer membranes enhances the ion permeability and drug release rates at the membrane phase transition. Biochimica et Biophysica Acta 2005, 1716(2):77-96.
22. Wright A. Drug loading and release from a thermally sensitive liposome. Mechanical Engineering and Materials Science 2006, Duke University, Durham.
23. Huang Q., Shan S., Braun R.D., Lanzen J., Anyrhambatla G., Kong G., Borelli M., Corry P., Dewhirst M.W., Li C.-Y. Noninvasive visualization of tumors in rodent dorsal skin window chambers. Nature Biotechnology 1999, 17(10):1033-1035.
24. Shan S., Sorg B., Dewhirst M.W. A novel rodent mammary window of orthotopic breast cancer for intravital microscopy. Microvascular Research 2003, 65(2):109-117.
25. Chen Q., Krol A., Wright A., Needham D., Dewhirst M.W., Yuan F. Tumor microvascular permeability is a key determinant for antivascular effects of doxorubicin encapsulated in a temperature sensitive liposome. International Journal of Hyperthermia 2008, 24(6):475-482.
26. Gaber M.H, Wu N.Z, Hong K., Huang S.K, Dewhirst M.W., Papahadjopoulos D. Thermosensitive liposomes: Extravasation and release of contents in tumor microvascular networks. International Journal of Radiation Oncology, Biology, Physics 1996, 36(5):1177-1187.
27. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting. Advances in Enzyme Regulation 2001, 41:189-207.
28. Maeda H.M.Y. Tumoritropic and lymphotropic principles of macromolecular drugs. Critical Reviews in Therapeutic Drug Carrier Systems 1989, 6(3):193-210.
29. Matteucci M.L., Anyarambhatla G., Rosner G., Azuma C., Fisher P.E., Dewhirst M.W., Needham D., Thrall D.E. Hyperthermia increases accumulation of technetium-99m-labeled liposomes in feline sarcomas. Clinical Cancer Research 2000, 6:3748.
30. Yarmolenko P.S., Zhao Y., Landon C., Spasojevic I., Yuan F., Needham D., Viglianti B.L., Dewhirst M.W. Comparative effects of thermosensitive doxorubicin-containing liposomes and hyperthermia in human and murine tumours. International Journal of Hyperthermia 2010, 26:485-498.
31. Ponce A.M., Viglianti B.L., Yu D., Yarmolenko P.S., Michelich C.R., Woo J., Bally M.B., Dewhirst M.W. Magnetic resonance imaging of temperature-sensitive liposome release: Drug dose painting and antitumor effects. Journal of National Cancer Institute 2007, 99(1):53-63.
32. Banno B., Ickenstein L.M., Chiu G.N.C., Bally M.B., Thewalt J., Brief E., Wasan E.K. The functional roles of poly(ethylene glycol)-lipid and lysolipid in the drug retention and release from lysolipid-containing thermosensitive liposomes in vitro and in vivo. Journal of Pharmaceutical Sciences 2010, 99(5):2295-2308.
33. Allen T.M., Hansen C., Martin F., Redemann C., Yau-Young A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochimica et Biophysica Acta 1991, 1066(1):29-36.
34. Boman N.L., Mayer L.D., Cullis P.R. Optimization of the retention properties of vincristine in liposomal systems. Biochimica et Biophysica Acta 1993, 1152(2):253-258.
35. Porschen R., Classen S., Piontek M., Borchard F. Vascularization of carcinomas of the esophagus and its correlation with tumor proliferation. Cancer Research 1994, 54:587-591.
36. Hauck M.L., LaRue S.M., Petros W.P., Poulson J.M., Yu D., Spasojevic I., Pruitt A.F., Klein A., Case B., Thrall D.E., Needham D., Dewhirst M.W. Phase I trial of doxorubicin-containing low temperature sensitive liposomes in spontaneous canine tumors. Clinical Cancer Research 2006, 12:4004-4010.
37. Yatvin M.B., Weinstein J.N., Dennis W.H., Blumenthal R. Design of liposomes for enhanced local release of drugs by hyperthermia. 1978, 202(4374):1290-1293.
38. Hossann M., Wiggenhorn M., Schwerdt A., Wachholz K., Teichert N., Eibl H., Issels R.D., Lindner L.H. In vitro stability and content release properties of phosphatidylglyceroglycerol containing thermosensitive liposomes. Biochimica et Biophysica Acta (BBA) -. Biomembranes 2007, 1768(10):2491-2499.
39. Koning G.A., Eggermont A.M.M., Lindner L.H., ten Hagen T.L.M. Hyperthermia and thermosensitive liposomes for improved delivery of chemotherapeutic drugs to solid tumors. Pharmaceutical Research 2010, 27:1750-1754.
40. Lindner L.H., Eichhorn M.E., Eibl H., Teichert N., Schmitt-Sody M., Issels R.D., Dellian M. Novel temperature-sensitive liposomes with prolonged circulation time. Clinical Cancer Research 2004, 10(6):2168-2178.
41. Lindner L.H., Hossann M., Vogeser M., Teichert N., Wachholz K., Eibl H., Hiddemann W., Issels R.D. Dual role of hexadecylphosphocholine (milte-fosine) in thermosensitive liposomes: Active ingredient and mediator of drug release. Journal of Controlled Release 2008, 125(2):112-120.
42. May J.P., Li S.D. Hyperthermia-induced drug targeting. Expert Opinion on Drug Delivery 2013, 10:511-527.
43. Issels, R.D.G., de Leeuw, A.A.C. (The Netherlands), Milani, V. (Germany), Ott, O. (Germany), Osinsky, S. (Ukraine), Rehak, P. (Austria), van Rhoon, G.C. (The Netherlands), Vaupel, P. (Germany), Wessalowski, R. (Germany) and Westermann, A. (The Netherlands). The European Society for Hyperthermic Oncology (ESHO). Available from: http://www.esho.info/.
44. Mertyna P., Dewhirst M.W., Halpern E., Goldberg W., Goldberg S.N. Radiofrequency ablation: The effect of distance and baseline temperature on thermal dose required for coagulation. International Journal of Hyperthermia 2008, 24(7):550-559.
45. Curley S.A., Izzo F., Ellis L.M., Vauthey J.N., Vallone P. Annals of Surgery 2000 September, 232(3):381-391.
46. Corporation Celsion A dose escalation, pharmacokinetics, and safety study of doxorubicin encapsulated in temperature-sensitive liposomes released through microwave therapy in the treatment of prostate cancer 2003-2009, NCT00061867.
47. Corporation Celsion A phase I dose escalation tolerability study of ThermoDox™ (thermally sensitive liposomal doxorubicin) in combination with radiofrequency ablation (RFA) of primary and metastatic tumors of the liver 2007-2009, (NCT00441376) Completed.
48. Mertyna P., Hines-Peralta A., Liu Z.J., Halpern E., Goldberg W., Goldberg S.N. Radiofrequency ablation: Variability in heat sensitivity in tumors and tissues. Journal of Vascular and Interventional Radiology 2007, 18:647-654.
49. Goldberg S.N., Gazelle G.S., Dawson S.L., Rittman W.J., Mueller P.R., Rosenthal D.I. Tissue ablation with radiofrequency: Effect of probe size, gauge, duration, and temperature on lesion volume. Academic Radiology 1995, 2:399-404.
50. Choi H., Loyer E.M., DuBrow R.A., Kaur H., David C.L., Huang S., Curley S., Charnsangavej C. Radio-frequency ablation of liver tumors: Assessment of therapeutic response and complications. RadioGraphics 2001, 21:S41-S54.
51. Poon R., Ng K., Yuen J., Hahne W., Prabhakar R., Eugeni M., Locklin J., Wood B., Libutti S. Phase I study of thermodox (thermally sensitive liposomes containing doxorubicin) given prior to radiofrequency ablation for unresectable liver cancers 2008.
52. Poon R.T., Borys N. Lyso-thermosensitive liposomal doxorubicin: A novel approach to enhance efficacy of thermal ablation of liver cancer. Expert Opinion on Pharmacotherapy 2009, 10(2):333-343.
53. Poon R.T.P. Combining ThermalAblation with Thermosensitive Liposomes. in Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2012, Lisbon Portugal.
54. Wood B.J., Poon R.T., Locklin J., Dreher M.R., Ng K.K., Eugeni M., Seidel G., Dromi S., Neeman Z., Kolf M., Black C.D.V., Prabhakar R., Libutti S.K. Phase I study of heat-deployed liposomal doxorubicin during radiofrequency ablation for hepatic malignancies. Journal of Vascular and Interventional Radiology i 2012, 23:248-255.
55. Phase 1/2 study of ThermoDox with approved hyperthermia in treatment of breast cancer recurrence at the chest wall (DIGNITY) 2012, Celsion Corporation, NCT00826085.
56. A randomized pivotal clinical trial in breast cancer patients of pre-operative focal microwave thermotherapy treatment for early-stage breast disease in intact breast 2001, Celsion Corporation, NCT00036998.
57. Vujaskovic Z. Chest Wall Recurrence of Breast Cancer Treated with Hyperthermia and Thermally Sensitive Liposomes (ThermoDox). Society for Thermal Medicine 2007, Washington, DC.
58. Rugo H.S. Breast Cancer Recurrences at the Chest Wall (BCRCW) When Standard Treatments (Tx) Have Failed: Lyso-Thermosensitive Liposomal Doxorubicin (LTLD) + Mild Local Hyperthermia. European Society of Medical Oncology October 2012, 28 September-2, Vienna, Austria.
59. Corporation Celsion Randomized, double blind, phase II trial of radiofrequency ablation +/- lyso-thermosensitive liposomal doxorubicin (Thermodox) for colorectal liver metastases greater than or equal to 2 cm maximum diameter 2011, (NCT01464593).
60. Corporation Celsion A Phase III, randomized, double-blinded, dummy-controlled study of the efficacy and safety of ThermoDox® (thermally sensitive liposomal doxorubicin) in combination with RFA compared to RFA-alone in the treatment of non-resectable hepatocellular carcinoma 2008-2012, (NCT00617981).
61. Tardugno M. Celsion Announces Results of Phase III HEAT Study of ThermoDox® in Primary Liver Cancer 2013, Celsion Corporation, Lawrenceville, N.J.
62. FDA U.S., Guidance for Industry. Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. Pharmacology and Toxicology 2005, U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER).
63. Rahman A., Carmichael D., Harris M., Roh J.K. Comparative pharmacokinetics of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes!. Cancer Research 1986, 46:2295-2299.
64. Dewhirst M.W., Viglianti B.L., Lora-Michiels M., Hanson M., Hoopes P.J. Basic principles of thermal dosimetry and thermal thresholds for tissue damage from hyperthermia. International Journal of Hyperthermiai 2003, 19(3):267-294.
65. Allen T., Cullis P. Drug delivery systems: Entering the mainstream. Science 2004, 303:1818-1822.
66. Dvorak H.F., Nagy J.A., Dvorak J.T., Dvorak A.M. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. American Journal of Pathology 1988, 133:95-109.
67. Gregoriadis G. The carrier potential of liposomes in biology and medicine I. The New England Journal of Medicine 1976, 295:704-710.
68. Gregoriadis G. The carrier potential of liposomes in biology and medicine II. The New England Journal of Medicine 1976, 295:765-770.
69. Yuan F.L.M., Huang S.K., Berk D.A., Papahadjopoulos D., Jain R.K. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Research 1994, 54:3352-3356.
70. Wu N.Z., Da D., Rudoll T.L., Needham D., Whorton A.R., Dewhirst M.W. Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue. Cancer Research 1993, 53:3765-3770.
71. Kong G., Braun R.D., Dewhirst M.W. Hyperthermia enables tumorspecific nanoparticle delivery: Effect of particle size. Cancer Research 2000, 60:4440-4445.
72. Kong G., Braun R.D., Dewhirst M.W. Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature. Cancer Research 2001, 61:3027-3032.
73. Reinhold H.S., Endrich B. Tumor microcirculation as a target for hyperthermia. International Journal of Hyperthermia 1986, 2:111-137.
74. Song C., Choi I., Nah B., Sahu S., Osborn J. Microvasculature and perfusion in normal tissues and tumors. Themo-Radiotherapy and Thermo-Chemotherapy 1995, Springer-Verlag, Berlin. M. Seegenschmiedt, P. Fessenden, C. Vernon (Eds.).
75. Yuan F., Dellian M., Fukumura D., Leunig M., Berk D.A., Torchilin V.P., Jain R.K. Vascular permeability in a human tumor xenograft: Molecular size dependence and cutoff size. Cancer Research 1995, 55:3752-3756.
76. Li L., ten Hagen T.L.M., Bolkestein M., Gasselhuber A., Yatvin J., van Rhoon G.C., Eggermont A.M.M., Haemmerich D., Koning G.A. Improved intra-tumoral nanoparticle extravasation and penetration by mild hyperthermia. Journal of Controlled Release 2013, 167(2):130-137.
77. Harrington K.J., Mohammadtaghi S., Uster P.S. M.S., Glass, D., Peters, A.M., Vile, R.G. and Stewart, J.S., Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clinical Cancer Research 2001, 7(2):243-254.
78. Bangham A.D., Standish M.M., Watkins J.C. Diffusion of univalent ions across the lamellae of swollen phospholipids. Journal of Molecular Biology 1965, 13(1):238-252.
79. Hope M.J., Bally M.B., Webb G., Cullis P.R. Production of large unilamellar vesicles by a rapid extrusion procedure - characterization of size distribution, trapped volume and ability to maintain a membrane-potential. Biochimica et Biophysica Acta 1985, 812(1):55-65.
80. Mayer L.D., Hope M.J., Cullis P.R. Vesicles of variable sizes produced by a rapid extrusion procedure. Biochimica et Biophysica Acta 1986, 858(1):161-168.
81. Maurer N., Fenske D.B., Cullis P.R. Developments in liposomal drug delivery systems. Expert Opinion on Biological Therapy 2001, 1(5):923-947.
82. Mouritsen O.G., Jorgensen K., Honger T. Permeability of Lipid Bilayers Near the Phase Transition, in Permeability and Stability of Lipid Bilayers 1995, CRC Press, Boca Raton, 137-160.
83. Evans E.A., Needham D. Physical properties of surfactant bilayer membranes: Thermal transitions, elasticity, rigidity, cohesion, and colloidal interactions. The Journal of Physics Chemistry 1987, 91(16):4219-4228.
84. Needham D., Nunn R.S. Elastic deformation and failure of lipid bilayer membranes containing cholesterol. Biophysical Journal 1990, 58:997-1009.
85. Needham D., Kim D. PEG-covered lipid surfaces: Bilayers and monolayers. Colloids and Surfaces B: Biointerfaces 2000, 183-195. K. Park (Ed.).
86. Needham D., Zhelev D. Chapter 9. Use of micropipet manipulation techniques to measure the properties of giant lipid vesicles. Giant Vesicles 2000, 103-147. John Wiley & Sons Ltd, Chichester. P.L. Luisi, P. Walde (Eds.).
87. Needham D., Mcintosh T.J., Zhelev D.V. Surface chemistry of the sterically stabilized PEG-liposome: General principles. Liposomes: Rational Design 1999, 13-62. Marcel Dekker, Inc, New York. A. Janoff (Ed.).
88. Needham D., Stoicheva N., Zhelev D.V. Exchange of monooleoylphosphatidylcholine as monomer and micelle with membranes containing poly(ethylene glycol)-lipid. Biophysical Journal 1997, 73(5):2615-2629.
89. Needham D., Zhelev D. The mechanochemistry of lipid vesicles examined by micropipet manipulation techniques. Vesicles 1996, 373. Marcell Dekker, New York. M. Rosoff (Ed.).
90. Yatvin M.B., Muhlensiepen H., Porschen W., Weinstein J.N., Feinendegen L.E. Selective delivery of liposome-associated cis-dichlorodiam mineplatinum(II) by heat and its influence on tumor drug uptake and growth. Cancer Research 1981, 41(5):1602-1607.
91. Israelachvili, J., Intermolecular and Surface Forces. 1992, Academic Press.
92. Kenworthy A.K., Hristova K., Needham D., McIntosh T.J. Range and magnitude of the steric pressure between bilayers containing phospholipids with covalently attached poly(ethylene glycol). Biophysical Journal 1995, 68(5):1921-1936.
93. Kucerka N., Nieh M.P., Katsaras J. Fluid phase lipid areas and bilayer thicknesses of commonly used phosphatidylcholines as a function of temperature. Biochimica et Biophysica Acta 2011, 1808:2761-2771.
94. Zhelev D.V. Exchange of monooleoylphosphatidylcholine with single egg phosphatidylcholine vesicle membranes. Biophysical Journal 1996, 71(1):257-273.
95. Haberland M.E., Reynolds J.A. Interaction of L-a-palmitoyl lysophosphatidylcholine with the AI polypeptide of high density lipoprotein The Journal of Biological Chemistry 1975, 250(17):6636-6639.
96. Ashok B., Arleth L., Hjelm R.P., Rubinstein I., Onyuksel H. In vitro characterization of PEGylated phospholipid micelles for improved drug solubilization: Effects of PEG chain length and PC incorporation. Journal of Pharmaceutical Sciences 2004, 93(10):2476-2487.
97. Rand R.P., Burton A.C. Mechanical properties of the red cell membrane. II, viscoelsatic breakdown of the membrane. Biophysical Journal 1964, 4:115.
98. Evans E., Skalak R. Mechanics and Thermodynamics of Biomembranes 1980, Boca Raton Florida, CRC.
99. Evans E., Hochmuth R.M. Mechanochemical properties of membranes. Current Topics in Membranes and Transport 1978, Academic Press, New York. F. Bonner, A. Kleinzeller (Eds.).
100. Meiselman H.J., Lichtman M.A., LaCelle P.L. White cell mechanics: Basic science and clinical aspects 1984, Liss, Alan R. Inc, New York.
101. Needham D. Possible role of cell cycle-dependent morphology, geometry, and mechanical-properties in tumor-cell metastasis. Cell Biophysics 1991, 18(2):99-121.
102. Evans E. Micromethods for measurement of deformability and adhesivity properties of blood cells and synthetic membrane vesicles. Physical Basis of Cell-Cell Adhesion 1988, CRC Press, Inc, Boca Raton, FL. P. Bongrand (Ed.).
103. Evans E., Kwok R. Mechanical calorimetry of large dimyristoylphosphatidylcholine vesicles in the phase transition region. Biochemistry 1982, 21:4874-4879.
104. Kwok R., Evans E. Thermoelasticity of large lecithin bilayer vesicles. Biophysical Journal 1981, 35:637-652.
105. Evans E., Needham D., Janzen J. Nonspecific adhesion of phospholipid bilayer membranes in solutions of plasma proteins. Proteins at Interfaces. Physicochemical and Biochemical Studies 1987, 88-103. J.L. Brash, T.A. Horbett (Eds.).
106. Ickenstein L.M., Arfvidsson M.C., Needham D., Mayer L.D., Edwards K. Disc formation in cholesterol-free liposomes during phase transition. Biochimica et Biophysica Acta 2003, 1614(2):135-138.
107. Sandstrom M., Ickenstein L.M., Mayer L.D., Edwards K. Effects of lipid segregation and lysolipid dissociation on drug release from thermosensitive liposomes. Journal of Controlled Release 2005, 107(1):131-142.
108. Kim D.H., Costello M. J., Duncan P.B. and Needham, D., Mechanical properties and microstructure of polycrystalline phospholipid monolayer shells - novel solid nanoparticles. Langmuir 2003, 19:8455-8466.
109. Kim D.H., Needham D. Lipids as bilayers and monolayers: Characterization using micropipet manipulation techniques. Encyclopedia of Surface and Colloid Science 2001, Marcel Dekker, Inc, New York, NY, Santa Barbara, CA. A. Hubbard (Ed.).
110. Needham D. Cohesion and permeability of lipid bilayer vesicles. Permeability and Stability of Lipid Bilayers 1995, 49-75. CRC Press, Inc, Boca Raton FL. E. Simon (Ed.).
111. Needham D., McIntosh T.J., Evans E.A. Thermomechanical and transition properties of dimyristoylphosphatidylcholine/cholesterol bilayers. Biochemistry 1988, 27:4668-4673.
112. Mabrey S., Sturtevant J.M. Investigation of phase transitions of lipids and lipid mixtures by high sensitivity differential scanning calorimetry. Proceedings of National Academy of Sciences USA 1976, 73(11):3862-3866.
113. Bloom M. E.E. and Mouritsen, O.G., Physical properties of the fluid lipid-bilayer component of cell membranes: A perspective. Quarterly Reviews of Biophysics 1991, 24(3):293-397.
114. Marsh D., Watts A., Knowles P.F. Evidence for phase boundary lipid. Permeability of tempo-choline into dimyristoylphosphatidylcholine vesicles at the phase transition. Biochemistry 1976, 15:3570-3578.
115. Kong G., Dewhirst M.W. Hyperthermia and liposomes. International Journal of Hyperthermia 1999, 15(5):345-370.
116. Needham D., Zhelev D.V. Lysolipid exchange with lipid vesicle membranes. Annals of Biomedical Engineering 1995, 23(3):287-298.
117. Needham D. Temperature-sensitive liposomal formulation U.S. Patent No. 6,200,598 (Filed: 18 June 1998) 2001.
118. Needham D. Temperature-sensitive liposomal formulation US Patent Office No. 6,726,925 (Filed: 9 December 1999) 2004, USA.
119. Forssen E.A., Tokes Z.A. In vitro and in vivo studies with adriamycin liposomes. Biochemical and Biophysical Research Communications 1979, 91:1295-1301.
120. Mayer L.D., Bally M.B., Cullis P.R. Strategies for optimizing liposomal doxorubicin. Journal of Liposome Research 1990, 1(4):463-480.
121. Frederick C.A., Williams L.D., Ughetto G., van der Mare G.A., van Boom J.H., Rich A., Wang A.H.J. Structural comparison of anticancer drug-DNA complexes: Adriamycin and daunomycin. Biochemistry 1990, 29:2538-2549.
122. Dalmark M., Johansen P. Molecular association between doxorubicin (adriamycin) and DNA derived bases, nucleosides, nucleotides, other aromatic compounds, and proteins in aqueous solution. Molecular Pharmacology 1982, 22:158-165.
123. Saltiel E., McGuire W. Doxorubicin (adriamycin) cardiomyopathy - A critical review. Western Journal of Medicine 1983, 139(3):332-341.
124. Rahman A., Kessler A., More N., Sikic B., Rowden G., Woolley P., Schein P.S. Liposomal protection of adriamycin-induced cardiotoxicity in mice. Cancer Research 1980, 40(5):1532-1537.
125. Cullis P.R., Mayer L.D., Bally M.B., Madden T.D., Hope M.J. Generating and loading of liposomal systems for drug-delivery applications. Advanced Drug Delivery Reviews 1989, 3:267-282.
126. Hristova K., Needham D. Influence of bilayer fluctuations on the steric interactions between polymer-grafted bilayers. Liquid Crystals 1995, 18(3):423-430.
127. Evans E., Rawicz W., Smith B.A. Concluding remarks back to the future: Mechanics and thermodynamics of lipid biomembranes. Faraday Discussions 2013, 161:591-611.
128. Webb M.S., Harasym T.O., Masin D., Bally M.B., Mayer L.D. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. British Journal of Cancer 1995, 72(4):896-904.
129. Vist M.R., Davis J.H. Phase equilibria of cholesterol/dipalmitoylphosphatidylcholine mixtures: 2H nuclear magnetic resonance and differential scanning calorimetry. Biochemistry 1990, 29(2):451-464.
130. Karmakar S., Raghunathan V.A., Mayor S. Phase behaviour of dipalmitoyl phosphatidylcholine (DPPC)-cholesterol membranes. Journal of Physics: Condensed Matter 2005, 17:S1177-S1182.
131. Needham D., Ponce Ana Nanoscale drug delivery vehicles for solid tumors: A new paradigm for localized drug delivery using temperature sensitive liposomes. Nanotechnology for Cancer Therapy 2006, 677-719. CRC Press. M.M. Amiji (Ed.).
132. FDA, U.S. Chemistry, Manufacturingand Controls (CMC) Guidances. Available from: http://www.fda.gov/drugs/guidancecomplianceregulatoryinformation/guidances/ucm064979.htm.
133. Waterhouse D.N., Tardi P.G., Mayer L.D., Bally M.B. A comparison of liposomal formulations of doxorubicin with drug administered in free form: Changing toxicity profiles. Drug Safety 2001, 24(12):903-920.
134. Mayer L.D., Bally M.B., Cullis P.R. Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. Biochimica et Biophysica Acta 1986, 857(1):123-126.
135. Li X., Cabral-Lilly D., Janoff A.S., Perkins W.R. Complexation of internalized doxorubicin into fiber bundles affects its release rate from liposomes. Journal of Liposome Research 2000, 10(1):15-27.
136. APWA. Top Ten Public Works Projects of the Century, Available from: http://www2.apwa.net/about/awards/toptencentury/default.htm.
137. Papahadjopoulos D., Allen T.M., Gabizon A., Mayhew E., Matthay K., Huang S.K., Lee K.D., Woodle M.C., Lasic D.D., Redemann E.A.C. Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy. Proceedings of National Academy of Sciences 1991, 88(24):11460-11464.
138. Chang H.-I., Yeh M.K. Clinical development of liposome-based drugs: Formulation, characterization, and therapeutic efficacy. International Journal of Nanomedicine 2012, 7:49-60.
139. Wang R., Billone P.S., Mullett W.M. Nanomedicine in action: An overview of cancer nanomedicine on the market and in clinical trials. Journal of Nanomaterials 2013, 2013:12.
140. Needham D. Temperature-sensitive liposome formulation 2001, US Patent 6,200,598.
141. Needham D. Temperature-sensitive liposomal formulation 2003, Australian Patent Office 749806 issued 6 March 2003.
142. Needham D. Temperature-sensitive liposomal formulation 2005, European Patent Office EP1089713 Granted 12 January 2005.
143. Needham D. Temperature-sensitive liposomal formulation 2005, Hong Kong Patent Office No: 1035673 issued 29 July 2005.
144. Needham D. Temperature-sensitive liposomal formulation 2005, Japanese Patent Office No. 2002518317 25 June 2002.
145. C.Corporation NEWS RELEASES Available from. http://investor.celsion.com/releases.cfm.
146. Corporation Celsion, Healthcare Philips Investigational New Drug/ Investigational Device Exemption (IND/IDE) Application for a Phase 2 Study of ThermoDox and MR-HIFUin Bone Cancer 2012, U.S. FDA, Ed.
147. Woo J., Chiu G.N.C., Karlsson G., Wasan E., Ickenstein L., Edwards K., Bally M.B. Use of a passive equilibration methodology to encapsulate cisplatin into preformed thermosensitive liposomes. International Journal of Pharmaceutics 2008, 349(1-2):38-46.
148. Park J.-Y., Chuchuen Oranat, Tovmasyan Artak, Dewhirst Mark W., Batinic-Haberle Ines, Needham David Liposome-mediated release of Mn porphyrin based cellular redox modulator: Comparison of two mn porphyrins of different lipophilicities 2013, in preparation.
149. Harrington K.J., Lewanski C.R., Northcote A.D., Whittaker J., Wellbank H., Vile R.G., Peters A.M., Stewart J.S. Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer. Annals of Oncology 2001, 12:493-496.
150. Kozubek A., Gubernator J., Przeworska E., Stasiuk M. Liposomal drug delivery, a novel approach: PLARosomes. Acta Biochimica Polonica 2000, 47:639-649.
151. Newman M.S., Colbern G.T., Working P.K., Engbers C., Amantea M.A. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemotherapy and Pharmacology 1999, 43:1-7.
152. Zamboni W.C., Gervais A.C., Egorin M.J., Schellens J.H., Zuhowski E.G., Pluim D., Joseph E., Hamburger D.R., Working P.K., Colbern G., Tonda M.E., Potter D.M., Eiseman J.L. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. Cancer Chemotherapy and Pharmacology 2004, 53:329-336.
153. Landon C., Park J.Y., Needham D., Dewhirst M.W. Nanoscale drug delivery and hyperthermia: The materials design and preclinical and clinical testing of low temperature-sensitive liposomes used in combination with mild hyperthermia in the treatment of local cancer. The Open Nanomedicine Journal Therapeutic Approaches and Drug Delivery, Wiley Interdisciplinary Reviews: Nanomedicine & Nanobiotechnology, John Wiley & Sons, Inc. 2011, 3:38-64.
154. Lindner L.H., Eichhorn M.E., Eibl H., Teichert N., Schmitt-Sody M., Issels R.D., Dellian M. Novel temperature-sensitive liposomes with prolonged circulation time. Clinical Cancer Research 2004, 10(6):2168-2178.
155. Hayashi H., Kono K., Takagishi T. Temperature-dependent associating property of liposomes modified with a thermosensitive polymer. Bioconjugate Chemistry 1998, 9(3):382-389.
156. Kono K., Yoshino K., Takagishi T. Effect of poly(ethylene glycol) grafts on temperature-sensitivity of thermosensitive polymer-modified liposomes. Journal of Controlled Release 2002, 80(1-3):321-332.
157. Paasonen L., Romberg B., Storm G., Yliperttula M., Urtti A., Hennink W.E. Temperature-sensitive poly(N-(2-hydroxypropyl) methacrylamide mono/dilactate)-coated liposomes for triggered contents release. Bioconjugate Chemistry 2007, 18(6):2131-2136.
158. Weinstein J.H., Magin R.L., Yatvin M.B., Zaharko D.S. Liposomes and local hyperthermia: Selective delivery of methotrexate to heated tumors. Science 1979, 204:188-191.
159. Estabrooks C.A. Will evidence-based nursing practice make practice perfect?. Canadian Journal of Nursing Research 1999, 30(4):273-294.
160. Ingersoll G.L. Evidence-based nursing: What it is and what it isn't. Nursing Outlook 2000, 48(4):151-152.